Next Generation Cancer Diagnostics Market Report: Trends, Forecast and Competitive Analysis to 2030

January 2024 | 150 pages | ID: N895F5AEF723EN
Lucintel

Abstracts

Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.

Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.

Contents

1. EXECUTIVE SUMMARY


2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET : MARKET DYNAMICS

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Next Generation Cancer Diagnostics Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Next Generation Cancer Diagnostics Market by Cancer Type
  3.3.1: Lung Cancer
  3.3.2: Breast Cancer
  3.3.3: Colorectal Cancer
  3.3.4: Cervical Cancer
  3.3.5: Others
3.4: Global Next Generation Cancer Diagnostics Market by Technology
  3.4.1: Next-generation Sequencing
  3.4.2: qPCR & Multiplexing
  3.4.3: Lab-on-a-chip & Reverse Transcriptase-PCR
  3.4.4: Protein Microarrays
  3.4.5: DNA Microarrays
3.5: Global Next Generation Cancer Diagnostics Market by Function
  3.5.1: Therapeutic Monitoring
  3.5.2: Companion Diagnostics
  3.5.3: Prognostics
  3.5.4: Cancer Screening
  3.5.5: Risk Analysis
3.6: Global Next Generation Cancer Diagnostics Market by Application
  3.6.1: Biomarker Development
  3.6.2: CTC Analysis
  3.6.3: Proteomic Analysis
  3.6.4: Epigenetic Analysis
  3.6.5: Genetic Analysis
  3.6.6: Others

4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030

4.1: Global Next Generation Cancer Diagnostics Market by Region
4.2: North American Next Generation Cancer Diagnostics Market
  4.2.1: North American Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  4.2.2: North American Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
4.3: European Next Generation Cancer Diagnostics Market
  4.3.1: European Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  4.3.2: European Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
4.4: APAC Next Generation Cancer Diagnostics Market
  4.4.1: APAC Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  4.4.2: APAC Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
4.5: ROW Next Generation Cancer Diagnostics Market
  4.5.1: ROW Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  4.5.2: ROW Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others

5. COMPETITOR ANALYSIS

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis

6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS

6.1: Growth Opportunity Analysis
  6.1.1: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Cancer Type
  6.1.2: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Technology
  6.1.3: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Function
  6.1.4: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Application
  6.1.5: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Region
6.2: Emerging Trends in the Global Next Generation Cancer Diagnostics Market
6.3: Strategic Analysis
  6.3.1: New Product Development
  6.3.2: Capacity Expansion of the Global Next Generation Cancer Diagnostics Market
  6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Next Generation Cancer Diagnostics Market
  6.3.4: Certification and Licensing

7. COMPANY PROFILES OF LEADING PLAYERS

7.1: Janssen Pharmaceuticals
7.2: Illumina
7.3: Novartis
7.4: F. Hoffmann-La Roche
7.5: Koninklijke Philips
7.6: QIAGEN
7.7: Agilent Technologies
7.8: Abbott
7.9: Thermo Fisher Scientific
7.10: GE HealthCare